DE69918697D1 - Neue sälze von hmg-coa reductase inhibitoren - Google Patents
Neue sälze von hmg-coa reductase inhibitorenInfo
- Publication number
- DE69918697D1 DE69918697D1 DE69918697T DE69918697T DE69918697D1 DE 69918697 D1 DE69918697 D1 DE 69918697D1 DE 69918697 T DE69918697 T DE 69918697T DE 69918697 T DE69918697 T DE 69918697T DE 69918697 D1 DE69918697 D1 DE 69918697D1
- Authority
- DE
- Germany
- Prior art keywords
- hmg
- coa reductase
- reductase inhibitors
- amine salts
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract 12
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title abstract 12
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 title abstract 12
- -1 amine salts Chemical class 0.000 abstract 6
- 238000000034 method Methods 0.000 abstract 3
- 238000002360 preparation method Methods 0.000 abstract 3
- 238000006243 chemical reaction Methods 0.000 abstract 2
- 238000000855 fermentation Methods 0.000 abstract 2
- 230000004151 fermentation Effects 0.000 abstract 2
- 241000894007 species Species 0.000 abstract 2
- 238000003786 synthesis reaction Methods 0.000 abstract 2
- 241000187643 Amycolatopsis Species 0.000 abstract 1
- 241000228212 Aspergillus Species 0.000 abstract 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 abstract 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 abstract 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 abstract 1
- 241000228347 Monascus <ascomycete fungus> Species 0.000 abstract 1
- 241000235395 Mucor Species 0.000 abstract 1
- 241000187654 Nocardia Species 0.000 abstract 1
- 241000228143 Penicillium Species 0.000 abstract 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 abstract 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 abstract 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 abstract 1
- 239000003529 anticholesteremic agent Substances 0.000 abstract 1
- 229960005370 atorvastatin Drugs 0.000 abstract 1
- 150000002596 lactones Chemical group 0.000 abstract 1
- 229960004844 lovastatin Drugs 0.000 abstract 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 abstract 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 abstract 1
- 229950009116 mevastatin Drugs 0.000 abstract 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 abstract 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 abstract 1
- 244000005700 microbiome Species 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 229960002965 pravastatin Drugs 0.000 abstract 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229960002855 simvastatin Drugs 0.000 abstract 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C211/09—Diamines
- C07C211/10—Diaminoethanes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C211/03—Monoamines
- C07C211/07—Monoamines containing one, two or three alkyl groups, each having the same number of carbon atoms in excess of three
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C211/09—Diamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C211/14—Amines containing amino groups bound to at least two aminoalkyl groups, e.g. diethylenetriamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
- C07C211/35—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SI9800240 | 1998-09-18 | ||
| SI9800240A SI20070A (sl) | 1998-09-18 | 1998-09-18 | Nove soli inhibitorjev HMG-CoA reduktaze |
| PCT/IB1999/001554 WO2000017150A1 (en) | 1998-09-18 | 1999-09-17 | NEW SALTS OF HMG-CoA REDUCTASE INHIBITORS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69918697D1 true DE69918697D1 (de) | 2004-08-19 |
| DE69918697T2 DE69918697T2 (de) | 2005-07-28 |
Family
ID=20432331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69918697T Expired - Lifetime DE69918697T2 (de) | 1998-09-18 | 1999-09-17 | Neue sälze von hmg-coa reductase inhibitoren |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US6583295B1 (de) |
| EP (2) | EP1466886A3 (de) |
| JP (1) | JP3834203B2 (de) |
| KR (1) | KR100699368B1 (de) |
| CN (1) | CN1228304C (de) |
| AT (1) | ATE271026T1 (de) |
| AU (1) | AU765373C (de) |
| CA (1) | CA2343646A1 (de) |
| DE (1) | DE69918697T2 (de) |
| HU (1) | HUP0103007A3 (de) |
| IL (1) | IL142055A (de) |
| IS (1) | IS2113B (de) |
| NZ (1) | NZ509583A (de) |
| SI (1) | SI20070A (de) |
| WO (1) | WO2000017150A1 (de) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0251582A (ja) * | 1988-08-12 | 1990-02-21 | Kyokado Eng Co Ltd | 地盤注入用薬液 |
| AU782143B2 (en) * | 1998-09-18 | 2005-07-07 | Lek Pharmaceuticals D.D. | Crystals of the sodium salt of pravastatin |
| SI20305A (sl) * | 1999-08-06 | 2001-02-28 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Kristali natrijeve soli pravastatina |
| SI1154979T1 (en) * | 1999-02-03 | 2005-10-31 | Institute For Drug Research Ltd. | Microbial process for preparing pravastatin |
| GB0003305D0 (en) | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
| ES2215050T3 (es) | 2000-06-09 | 2004-10-01 | Lek Pharmaceutical And Chemical Co. D.D. | Composicion estabilizada farmaceuticamente eficaz y formulacion farmaceutica que la comprende. |
| US6806290B2 (en) | 2000-06-09 | 2004-10-19 | Lek Pharmaceuticals D.D. | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
| CN1468098A (zh) * | 2000-10-05 | 2004-01-14 | �ݰ¸Ƕ�ҩ������˾ | 基本上无普伐他汀内酯和表普伐他汀的普伐他汀钠和包含普伐他汀钠的组合物 |
| JP2002121172A (ja) * | 2000-10-16 | 2002-04-23 | Sankyo Co Ltd | プラバスタチン又はその薬理上許容される塩の精製方法 |
| NL1017548C2 (nl) | 2001-03-09 | 2002-09-10 | Synthon Bv | Een lactonisatie proces. |
| US7642286B2 (en) * | 2001-06-21 | 2010-01-05 | Andrx Pharmaceuticals, Inc. | Stable pharmaceutical compositions containing pravastatin |
| JP2003026634A (ja) * | 2001-07-17 | 2003-01-29 | Mercian Corp | プラバスタチンナトリウム塩の製造方法 |
| JP2003093045A (ja) * | 2001-09-26 | 2003-04-02 | Godo Shusei Co Ltd | 有用変換微生物 |
| AU2003276960A1 (en) * | 2002-06-13 | 2003-12-31 | Novartis Ag | Calcium salts of indole derived statins |
| US20060019269A1 (en) * | 2002-10-17 | 2006-01-26 | Decode Genetics, Inc. | Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment |
| US20080293750A1 (en) * | 2002-10-17 | 2008-11-27 | Anna Helgadottir | Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment |
| WO2005014541A1 (en) * | 2003-08-12 | 2005-02-17 | Biocon Limited | Novel antihypercholesterolemic compound |
| US7396927B2 (en) | 2003-08-28 | 2008-07-08 | Teva Pharmaceutical Industries Ltd. | Process for preparation of rosuvastatin calcium |
| EP1663969A1 (de) * | 2003-09-17 | 2006-06-07 | Warner-Lambert Company LLC | Kristalline formen von [r-(r*,r*)]-2-(4-fluorphenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrol-1-heptansäure |
| GB0324791D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
| WO2005051921A1 (en) * | 2003-11-24 | 2005-06-09 | Teva Pharmaceutical Industries Ltd. | Crystalline ammonium salts of rosuvastatin |
| WO2005077916A1 (en) * | 2004-01-19 | 2005-08-25 | Ranbaxy Laboratories Limited | Salts of hmg-coa reductase inhibitors and use thereof |
| US7244844B2 (en) | 2003-12-02 | 2007-07-17 | Teva Pharmaceutical Industries Ltd. | Reference standard for characterization of rosuvastatin |
| US8158362B2 (en) * | 2005-03-30 | 2012-04-17 | Decode Genetics Ehf. | Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype |
| US20100216863A1 (en) * | 2004-01-30 | 2010-08-26 | Decode Genetics Ehf. | Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment |
| JP2007536373A (ja) | 2004-05-05 | 2007-12-13 | ファイザー・プロダクツ・インク | アトルバスタチンの塩形態 |
| JP2007508379A (ja) | 2004-07-13 | 2007-04-05 | テバ ファーマシューティカル インダストリーズ リミティド | Ｔｅｍｐｏ媒介型酸化段階を包含するロスバスタチンの調製方法 |
| US20090042979A1 (en) * | 2004-08-06 | 2009-02-12 | Transform Pharmaceuticals Inc. | Novel Statin Pharmaceutical Compositions and Related Methods of Treatment |
| WO2006017692A2 (en) * | 2004-08-06 | 2006-02-16 | Transform Pharmaceuticals, Inc. | Novel fenofibrate formulations and related methods of treatment |
| MX2007001553A (es) * | 2004-08-06 | 2008-03-07 | Transform Pharmaceuticals Inc | Nuevas composiciones farmaceuticas de estatina y metodos de tratamiento relacionados. |
| WO2006072963A1 (en) * | 2005-01-10 | 2006-07-13 | Concord Biotech Limited | Process for preparing simvastatin from lovastatin amine salts in three steps |
| CA2680693A1 (en) | 2005-02-22 | 2006-08-31 | Teva Pharmaceutical Industries Ltd. | Preparation of rosuvastatin |
| CA2499047A1 (en) * | 2005-03-01 | 2006-09-01 | Apotex Pharmachem Inc. | Process for producing atorvastatin hemicalcium |
| JP4813841B2 (ja) * | 2005-07-25 | 2011-11-09 | キユーピー株式会社 | プラバスタチンナトリウムの製造方法 |
| MX2007004427A (es) | 2005-08-16 | 2007-06-14 | Teva Pharma | Intermedio de rosuvastatina cristalina. |
| PL211815B1 (pl) * | 2007-11-19 | 2012-06-29 | Inst Chemii Organicznej Polska Akademia Nauk | Enzym esteraza lowastatyny osadzony na nośniku nierozpuszczalnym w wodzie, sposób osadzania enzymu, zastosowanie enzymu esterazy lowastatyny osadzonego na nosniku nierozpuszczalnym w wodzie, przepływowy reaktor biokatalityczny ze złożem oraz sposób wytwarzania i/lub oczyszczania symwastatyny |
| WO2009078033A2 (en) * | 2007-12-18 | 2009-06-25 | Themis Medicare Limited | Isolation and recovery of simvastatin in lactone form or in the form of an acid salt from the harvested fermentation broth |
| WO2011089559A1 (en) * | 2010-01-22 | 2011-07-28 | Orchid Chemicals And Pharmaceuticals Limited | A novel polymorphic form of atorvastatin salts |
| WO2012063115A2 (en) | 2010-11-11 | 2012-05-18 | Jubilant Life Sciences Ltd. | Process for the preparation of rosuvastatin calcium via novel amine intermediate |
| CN114031496B (zh) * | 2021-11-30 | 2024-09-27 | 广东蓝宝制药有限公司 | 一种高纯度普伐他汀1,1,3,3-四甲基丁胺的制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4319039A (en) * | 1979-06-15 | 1982-03-09 | Merck & Co., Inc. | Preparation of ammonium salt of hypocholesteremic fermentation product |
| ES493726A0 (es) | 1979-07-27 | 1981-06-16 | Sankyo Co | Un procedimiento para la preparacion de sales y esteres, de monacolina k utiles como agentes antitlipercolesteremicos. |
| US4342767A (en) | 1980-01-23 | 1982-08-03 | Merck & Co., Inc. | Hypocholesteremic fermentation products |
| MX7065E (es) | 1980-06-06 | 1987-04-10 | Sankyo Co | Un procedimiento microbiologico para preparar derivados de ml-236b |
| JPS57123140A (en) | 1981-01-23 | 1982-07-31 | Sankyo Co Ltd | Ml-236b carboxylic acid amine salt and remedy for hyperlipemia containing said salt as active component |
| JPS57185275A (en) * | 1981-05-07 | 1982-11-15 | Sankyo Co Ltd | Tetrahydro-dum-4 and tetrahydro-isodum-4 and their derivatives |
| US4997848A (en) | 1987-10-27 | 1991-03-05 | Sankyo Company, Limited | Octahydronaphthalene oxime derivatives for cholesterol synthesis inhibition |
| US5089523A (en) | 1990-05-11 | 1992-02-18 | E. R. Squibb & Sons, Inc. | Fluorinated derivatives of mevinic acids |
| US5223415A (en) * | 1990-10-15 | 1993-06-29 | Merck & Co., Inc. | Biosynthetic production of 7-[1',2',6',7',8',8a'(R)-hexahydro-2'(S),6'(R)-dimethyl-8'(S)-hydroxy-1'(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid) |
| HU9203780D0 (en) * | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
| HU221849B1 (hu) | 1991-12-12 | 2003-02-28 | Novartis Ag. | HMG-CoA reduktáz inhibitor fluvasztatint tartalmazó stabilizált gyógyszerkészítmények |
| US5763653A (en) | 1997-03-13 | 1998-06-09 | Ranbaxy Laboratories, Ltd. | Key intermediates in the manufacture of simvastatin |
| US5763646A (en) * | 1997-03-13 | 1998-06-09 | Ranbaxy Laboratories, Ltd. | Process for manufacturing simvastatin from lovastatin or mevinolinic acid |
| SI20305A (sl) * | 1999-08-06 | 2001-02-28 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Kristali natrijeve soli pravastatina |
-
1998
- 1998-09-18 SI SI9800240A patent/SI20070A/sl not_active IP Right Cessation
-
1999
- 1999-09-17 JP JP2000574060A patent/JP3834203B2/ja not_active Expired - Lifetime
- 1999-09-17 WO PCT/IB1999/001554 patent/WO2000017150A1/en not_active Ceased
- 1999-09-17 CA CA002343646A patent/CA2343646A1/en not_active Abandoned
- 1999-09-17 DE DE69918697T patent/DE69918697T2/de not_active Expired - Lifetime
- 1999-09-17 EP EP04011699A patent/EP1466886A3/de not_active Withdrawn
- 1999-09-17 CN CNB998110736A patent/CN1228304C/zh not_active Expired - Lifetime
- 1999-09-17 IL IL14205599A patent/IL142055A/en not_active IP Right Cessation
- 1999-09-17 NZ NZ509583A patent/NZ509583A/en not_active IP Right Cessation
- 1999-09-17 AT AT99941798T patent/ATE271026T1/de active
- 1999-09-17 AU AU55285/99A patent/AU765373C/en not_active Expired
- 1999-09-17 HU HU0103007A patent/HUP0103007A3/hu unknown
- 1999-09-17 KR KR1020017000758A patent/KR100699368B1/ko not_active Expired - Fee Related
- 1999-09-17 EP EP99941798A patent/EP1114021B1/de not_active Expired - Lifetime
- 1999-09-17 US US09/787,387 patent/US6583295B1/en not_active Expired - Lifetime
-
2001
- 2001-03-15 IS IS5891A patent/IS2113B/is unknown
-
2002
- 2002-12-16 US US10/320,285 patent/US6838566B2/en not_active Expired - Lifetime
-
2004
- 2004-10-15 US US10/966,000 patent/US20050049422A1/en not_active Abandoned
-
2007
- 2007-09-18 US US11/901,634 patent/US20080188552A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0103007A3 (en) | 2003-10-28 |
| DE69918697T2 (de) | 2005-07-28 |
| SI20070A (sl) | 2000-04-30 |
| AU765373C (en) | 2005-05-26 |
| AU5528599A (en) | 2000-04-10 |
| US6583295B1 (en) | 2003-06-24 |
| HUP0103007A2 (hu) | 2002-05-29 |
| IL142055A0 (en) | 2002-03-10 |
| AU765373B2 (en) | 2003-09-18 |
| US20080188552A1 (en) | 2008-08-07 |
| NZ509583A (en) | 2003-10-31 |
| CN1228304C (zh) | 2005-11-23 |
| WO2000017150A1 (en) | 2000-03-30 |
| EP1114021B1 (de) | 2004-07-14 |
| US20030120086A1 (en) | 2003-06-26 |
| KR20010071959A (ko) | 2001-07-31 |
| CA2343646A1 (en) | 2000-03-30 |
| US20050049422A1 (en) | 2005-03-03 |
| CN1318046A (zh) | 2001-10-17 |
| ATE271026T1 (de) | 2004-07-15 |
| IL142055A (en) | 2004-06-20 |
| JP2002526467A (ja) | 2002-08-20 |
| IS5891A (is) | 2001-03-15 |
| EP1114021A1 (de) | 2001-07-11 |
| EP1466886A2 (de) | 2004-10-13 |
| KR100699368B1 (ko) | 2007-03-27 |
| JP3834203B2 (ja) | 2006-10-18 |
| US6838566B2 (en) | 2005-01-04 |
| EP1466886A3 (de) | 2009-02-25 |
| IS2113B (is) | 2006-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69918697D1 (de) | Neue sälze von hmg-coa reductase inhibitoren | |
| IL187261A0 (en) | Crystals of the sodium salt of pravastatin | |
| PL347686A1 (en) | Stable pharmaceutical formulation comprising a hmg-coa reductase inhibitor | |
| NO20025784D0 (no) | Stabilisert farmasöytisk effektiv sammensetning og farmasöytisk formuleringsom innbefatter samme | |
| ATE284396T1 (de) | Verfahren zur bereitstellung von hochreinen hmg- coa reductase hemmer | |
| AU1510800A (en) | Process for the preparation of simvastatin and analogs thereof | |
| ATE164886T1 (de) | Biochemische reinigung von simvastatin | |
| CA2053000A1 (en) | Biosynthetic production of 6(r)-[2-(8(s)-hydroxy-2(s), 6(r)-dimethyl-1,2,6,7,8,8a(r)-hexahydronaphthyl)-ethyl]-4 (r)-hydroxy-3,4,5,6-tetrahydro-2h-pyran-2-one triol acid by enzymatic hydrolysis of lovastatin acid using an enzyme derived from__lonostachys compactiuscula | |
| AU2000250960A1 (en) | Stable pharmaceutical product and formulation | |
| YU88602A (sh) | Stabilizovane farmaceutski efektivne smeše i farmaceutske formulacije koje ih sadrže |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: LEK PHARMACEUTICALS D.D., LJUBLJANA, SI |